JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
We now rank 3rd in pharmaceutical production by volume and 14th by value
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
The net-zero target approval complements the company's near-term emission reduction targets
Professor G. D. Yadav is one of India’s most prolific and accomplished engineering-scientists, holding the prestigious National Science Chair from the Government of India
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
India's bio economy has experienced remarkable growth, skyrocketing from US $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
The new bioeconomy policy rolled out by the Modi government is set to place India as a global leader in the years to come
Capital expenditure expected to moderate to Rs. 5.6 billion in FY2025 from an estimated Rs. 7.6 billion in FY2024
Subscribe To Our Newsletter & Stay Updated
